Abstract
Childhood tuberculosis (TB) continues to be a neglected disease in areas where limited resources restrict the focus of national TB control programmes to only the most infectious sputum smear-positive cases. However, appreciation that children contribute a significant proportion to the global TB disease burden and suffer severe TB-related morbidity and mortality is growing. The World Health Organization (WHO) published guidelines on the management of paediatric TB in 2006 and child friendly drug formulations have been made available to deserving nations via the Global Drug Facility (GDF) since 2008. These advances also served to emphasize the considerable programmatic barriers that remain in resource- limited settings. This review provides an overview of current treatment practices, presenting the authors personal perspectives on issues related to the treatment of childhood TB, together with a brief synopsis of potential future treatment options.
Keywords: Pediatric tuberculosis, management, treatment, TB, infectious sputum, GDF, current treatment practices, childhood TB, future treatment options, children, bacterial pneumonia, HIV, respiratory disease, first-line antibiotics, endemic areas
Infectious Disorders - Drug Targets
Title: Management of Tuberculosis in Children and New Treatment Options
Volume: 11 Issue: 2
Author(s): B. J. Marais, H. S. Schaaf and P. R. Donald
Affiliation:
Keywords: Pediatric tuberculosis, management, treatment, TB, infectious sputum, GDF, current treatment practices, childhood TB, future treatment options, children, bacterial pneumonia, HIV, respiratory disease, first-line antibiotics, endemic areas
Abstract: Childhood tuberculosis (TB) continues to be a neglected disease in areas where limited resources restrict the focus of national TB control programmes to only the most infectious sputum smear-positive cases. However, appreciation that children contribute a significant proportion to the global TB disease burden and suffer severe TB-related morbidity and mortality is growing. The World Health Organization (WHO) published guidelines on the management of paediatric TB in 2006 and child friendly drug formulations have been made available to deserving nations via the Global Drug Facility (GDF) since 2008. These advances also served to emphasize the considerable programmatic barriers that remain in resource- limited settings. This review provides an overview of current treatment practices, presenting the authors personal perspectives on issues related to the treatment of childhood TB, together with a brief synopsis of potential future treatment options.
Export Options
About this article
Cite this article as:
J. Marais B., S. Schaaf H. and R. Donald P., Management of Tuberculosis in Children and New Treatment Options, Infectious Disorders - Drug Targets 2011; 11 (2) . https://dx.doi.org/10.2174/187152611795589645
DOI https://dx.doi.org/10.2174/187152611795589645 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Enzymological Characterization of Some 2-(Substitutedphenylamino) quinazolin-4(3H)-one Derivatives as Potent α-Glucosidase Inhibitors In Vitro
Letters in Drug Design & Discovery Hemoglobin Degrading Proteases of Plasmodium falciparum as Antimalarial Drug Targets
Current Drug Targets Editorial (Thematic Issue: Drug Delivery Australia)
Current Drug Delivery Natures Medicines: Traditional Knowledge and Intellectual Property Management. Case Studies from the National Institutes of Health (NIH), USA
Current Drug Discovery Technologies The Use of SIFT-MS in Profiling the Faecal Volatile Metabolome in Horses with Colic: A Pilot Study
Current Analytical Chemistry Synthesis and In Vitro Antimicrobial Evaluation of 4-alkyl/aryl-1-(3-phenoxypropionyl)-thiosemicarbazides
Letters in Drug Design & Discovery Th17 Cells: The Role in Immunity
Current Immunology Reviews (Discontinued) Inhibitors of the Sulfur Assimilation Pathway in Bacterial Pathogens as Enhancers of Antibiotic Therapy
Current Medicinal Chemistry Autophagy: For Better or for Worse, in Good Times or in Bad Times …
Current Molecular Medicine Transmucosal Delivery of Linagliptin for the Treatment of Type- 2 Diabetes Mellitus by Ultra-Thin Nanofibers
Current Drug Delivery Insights into Antimicrobial Peptides from Spiders and Scorpions
Protein & Peptide Letters <i>In Vitro</i> Evaluation of Immunogenicity of Recombinant OMP25 Protein Obtained from <i>Endemic Brucella</i> abortus Biovar 3 as Vaccine Candidate Molecule Against Animal Brucellosis
Protein & Peptide Letters Advance Synthetic Approaches to 1,2,3-triazole Derived Compounds: State of the Art 2004-2020
Current Organocatalysis Targeting Bacterial Metalloenzymes: A New Strategy for the Development of Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry Gene Therapy by Liver Transplantation and Single Stranded Oligonucleotides (SSOs) in Familial Amyloidotic Polyneuropathy (FAP)
Current Pharmacogenomics Structure of the Cytoplasmic Segment of Histidine Kinase Receptor QseC: A Key Player in Bacterial Virulence
Protein & Peptide Letters Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes
Current Pharmacogenomics Uveitis in Horses, Rats and Man: What Do We Learn from Our Pets?
Current Immunology Reviews (Discontinued) Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal Use of Peptide Libraries for Identification and Optimization of Novel Antimicrobial Peptides
Current Topics in Medicinal Chemistry